UPCC 06518: A Phase 2 Precision Oncology Study of Biomarker-Directed Pembrolizumab-Based Combination Therapy for Advanced Non-Small Cell Lung Cancer
Brief description of study
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
lung cancer
-
Age: - 99 Years
-
Gender: All
Updated on
29 Jan 2020.
Study ID: 831302
